Immunomonitoring measures in relapsing-remitting multiple sclerosis

被引:11
|
作者
Matsui, M [1 ]
Araya, S
Wang, HY
Matsushima, K
Saida, T
机构
[1] Natl Utano Hosp, Ctr Neurol Dis, Clin Res Ctr, Ukyo Ku, Kyoto 6168255, Japan
[2] Natl Utano Hosp, Dept Neurol, Ukyo Ku, Kyoto 6168255, Japan
[3] Univ Tokyo, Sch Med, Dept Mol Prevent Med, Tokyo 1130033, Japan
关键词
multiple sclerosis; flow cytometry; cytokine; surface antigen;
D O I
10.1016/j.jneuroim.2003.11.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Forty-five patients with relapsing-remitting multiple sclerosis (MS) were examined to determine intracellular cytokine profiles and the surface phenotype of circulating lymphocytes during active, recovery, and stable stages. Active stage patients were characterized by decreases in CD4(+)IL-4(+) Th2 as well as CD4(+)IFN-gamma(+) Th1 cells, when compared with stable stage patients and 16 healthy controls. CCR4(+) Th2 cells were persistently decreased at every MS stage as compared to the controls. CD4(+)CD29(+) and CD4(+)CXCR3(+) cells were closely correlated with IFN-gamma-producing cells. These findings suggest that simultaneous flow cytometry for these two types of measurements can provide information concerning current immune status in MS. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:192 / 199
页数:8
相关论文
共 50 条
  • [1] Relapsing-remitting multiple sclerosis
    Flores, A
    Ochoa, E
    Zamora, S
    Barrientos, UN
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 214 (1-2) : 110 - 110
  • [2] Autohemotherapy for relapsing-remitting multiple sclerosis
    Mubaidin, AF
    Horani, KA
    Dehayyat, MA
    Shehab, M
    Abu-Ruman, IA
    Shurbaji, AA
    Kurdi, A
    Hiari, M
    Khakish, M
    Harahsheh, O
    Dabbas, M
    [J]. NEUROLOGY, 2001, 56 (08) : A75 - A75
  • [3] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Guo, Rui
    Zhang, Fubo
    Zhang, Chao
    Dong, Shuai
    Zhou, Hongyu
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [4] Relapsing-remitting tumefactive multiple sclerosis
    Selkirk, SM
    Shi, J
    [J]. MULTIPLE SCLEROSIS, 2005, 11 (06): : 731 - 734
  • [5] Depression in relapsing-remitting multiple sclerosis
    Mendes, MF
    Tilbery, CP
    Balsimelli, S
    Moreira, MA
    Barao-Cruz, AM
    [J]. ARQUIVOS DE NEURO-PSIQUIATRIA, 2003, 61 (3A) : 591 - 595
  • [6] Rituximab in relapsing-remitting multiple sclerosis
    Schrijver, Hans M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24): : 2645 - 2645
  • [7] Fingolimod for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Tramacere, Irene
    Firwana, Belal
    Pacchetti, Ilaria
    Palumbo, Roberto
    Filippini, Graziella
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [8] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [9] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Zhou, Hongyu
    Han, Wenjie
    Zhang, Shihong
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12):
  • [10] Natalizumab for relapsing-remitting multiple sclerosis
    Horga, A.
    Tintore, M.
    [J]. NEUROLOGIA, 2011, 26 (06): : 357 - 368